Creso to cultivate medicinal cannabis in Colombia

By Meagan Evans. Published at Jun 12, 2018, in Biotech

Creso Pharma Limited (ASX:CPH) today announced that Kunna S.A.S, the wholly owned Colombian subsidiary of Kunna Canada Ltd has been granted a licence to cultivate medicinal cannabis in Colombia.

This news comes as CPH’s due diligence on its proposed acquisition of Kunna Canada Ltd. (and Kunna S.A.S.) continues, and is due for completion later this month.

Once the acquisition of Kunna is finalised, CPH will be one of only a few companies globally — and the only medicinal cannabis company listed on the ASX — with the capacity to commercially cultivate medicinal-grade cannabis in Colombia.

This is a significant market opportunity as Colombia has one of the most comprehensive and sophisticated medicinal cannabis frameworks in Latin America.

In 2017, Colombia was allocated a production quota of 40.5 tonnes — equivalent to one quarter of the world’s total production by the International Narcotics Control Board (INCB), the UN’s body responsible for regulating the legal cannabis market. This is the largest allocation of any country and is over and above the United States’ allocation of medicinal marijuana for both internal and external use with 33.4 tonnes approved.

Colombia is a significantly cost-effective location to cultivate medicinal cannabis, particularly when compared to North America. In Colombia, cost of goods sold (COGS) for a gram of cannabis flower equivalent can be as low as just $0.35 cents vs $1.57 in Canada, and trimming rate per gram is $0.10 vs $0.50 in Canada. In addition, the average cost of planting over 46 hours is $200 versus $860 in Canada.

The acquisition of Kunna and the grant of the cultivation licence will not only provide the capacity to commercially cultivate medicinal-grade cannabis in Colombia, but will give CPH a strong springboard to the strategically important Latin American market, which now includes Argentina, Colombia, Chile, Mexico and Uruguay.

It also gives CPH the ability to greater integrate its supply chain, allowing it to produce its own medicinal cannabis as well as supply its existing planned products to the Colombian market and export to the broader Latin America market.

The advancement into Colombia is part of Creso’s broader aim to establish operations which reach all key global markets. Creso’s Canadian medicinal cannabis operations are set up towards supplying North America, its Israeli operations towards supplying Europe and now its Colombia operations towards supplying Latin America.

At the same time, it’s worth noting that this is an early stage play and investors should seek professional financial advice if considering this company for their portfolio.

Dr Miri Halperin Wernli, CPH CEO and co-founder said: “We are really excited about the opportunity that the acquisition of Kunna and its licence to cultivate provides us. It will allow us to bring Creso’s pharmaceutical expertise and methodological rigour to medicinal cannabis production and cultivation in Colombia.

“We know from our pharmaceutical experience that a foothold in Colombia provides a great springboard into the rest of Latin America. In addition, from a product perspective, Colombia offers varied genetics and the ability to grow high quality products at low cost.”

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Facebook
Twitter
LinkedIn